SphingoTec Closes €5M Series C to Accelerate Market Development

SphingoTec GmbH has successfully secured €5 million in Series C financing to drive its global expansion and financial growth. The investment round was led by Think.Health Ventures, with support from existing investors. This capital injection will play a crucial role in out-licensing and commercializing SphingoTec’s innovative biomarkers for critical care, aimed at significantly improving patient management and outcomes.

Think.Health Ventures' expertise in diagnostics and its extensive network will add considerable value to SphingoTec. Additionally, the company will continue to collaborate with key players in the diagnostic industry to penetrate the US market and beyond.

SphingoTec focuses on developing and marketing novel blood-based biomarkers like Proenkephalin A 119-159 (penKid) and bioactive Adrenomedullin 1-52 (bio-ADM). These biomarkers are designed to enhance the assessment of kidney and endothelial functions, respectively, and are crucial in managing critically ill patients.

Deborah Bergmann, Managing Director and CEO, stated, "With this investment, we will focus on further out-licensing our biomarkers to translate scientific advancements into routine clinical practice, ultimately supporting clinicians in improving patient outcomes."